Phase I study of ruxolitinib with radiation and temozolomide in patients with newly diagnosed grade III gliomas and glioblastoma.

Yasmeen Rauf; Rachel Hufsey; Kathy Robinson; John H. Suh; Samuel T. Chao; Erin Sennett Murphy; Jennifer S. Yu; David M. Peereboom; Manmeet Singh Ahluwalia; Wei Wei

doi:10.1200/JCO.2021.39.15_SUPPL.2060

Phase I study of ruxolitinib with radiation and temozolomide in patients with newly diagnosed grade III gliomas and glioblastoma.

Yasmeen Rauf
, Rachel Hufsey
, Kathy Robinson
, John H. Suh
, Samuel T. Chao
, Erin Sennett Murphy
, Jennifer S. Yu
, David M. Peereboom
, Manmeet Singh Ahluwalia
, Wei Wei

Herbert Wertheim Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Journal of Clinical Oncology
Volume	39
DOIs	https://doi.org/10.1200/JCO.2021.39.15_SUPPL.2060
State	Published - May 28 2021

Disciplines

Medicine and Health Sciences
Oncology

Access to Document

10.1200/JCO.2021.39.15_SUPPL.2060License: Unspecified

Cite this

@article{7ec9a73a980347d79f266d4c76ca3b86,

title = "Phase I study of ruxolitinib with radiation and temozolomide in patients with newly diagnosed grade III gliomas and glioblastoma.",

author = "Yasmeen Rauf and Rachel Hufsey and Kathy Robinson and Suh, \{John H.\} and Chao, \{Samuel T.\} and Murphy, \{Erin Sennett\} and Yu, \{Jennifer S.\} and Peereboom, \{David M.\} and Ahluwalia, \{Manmeet Singh\} and Wei Wei",

note = "2060 Background: Ruxolitinib is a novel, potent, and selective inhibitor of JAK1 (Janus kinase 1) and JAK2 with modest to marked selectivity against TYK2 (tyrosine kinase 2) and JAK3, respectively. Ruxolitinib interferes with the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function.",

year = "2021",

month = may,

day = "28",

doi = "10.1200/JCO.2021.39.15\_SUPPL.2060",

language = "American English",

volume = "39",

journal = "Journal of Clinical Oncology",

}

TY - JOUR

T1 - Phase I study of ruxolitinib with radiation and temozolomide in patients with newly diagnosed grade III gliomas and glioblastoma.

AU - Rauf, Yasmeen

AU - Hufsey, Rachel

AU - Robinson, Kathy

AU - Suh, John H.

AU - Chao, Samuel T.

AU - Murphy, Erin Sennett

AU - Yu, Jennifer S.

AU - Peereboom, David M.

AU - Ahluwalia, Manmeet Singh

AU - Wei, Wei

N1 - 2060 Background: Ruxolitinib is a novel, potent, and selective inhibitor of JAK1 (Janus kinase 1) and JAK2 with modest to marked selectivity against TYK2 (tyrosine kinase 2) and JAK3, respectively. Ruxolitinib interferes with the signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function.

PY - 2021/5/28

Y1 - 2021/5/28

UR - https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.2060

U2 - 10.1200/JCO.2021.39.15_SUPPL.2060

DO - 10.1200/JCO.2021.39.15_SUPPL.2060

M3 - Article

VL - 39

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Phase I study of ruxolitinib with radiation and temozolomide in patients with newly diagnosed grade III gliomas and glioblastoma.

Disciplines

Access to Document

Other files and links

Cite this